Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Terephthalamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.56 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terephthalamide SCHEMBL23774 | 0.87 | PARP1 (0.71) | CA2CA1CA12CA9CA14 | |
| Benzamide SCHEMBL1330139 | 0.87 | PARP1 (0.80) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1498165 | 0.85 | CA2 (0.68) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL28360111 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL15328883 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL1087289 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL11512422 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL1906838 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL29102653 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 | |
| Terephthalamide SCHEMBL689841 | 0.84 | PARP1 (0.67) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES LLC (US) | 2016-10-20 | — | — | US | disclosed |
| US-9346845-B2 | Anionic conjugates of glycosylated bacterial metabolite | GLYCAN BIOSCIENCES LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | Glycosynnovations Pty Ltd (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8791245-B2 | Anionic conjugates of glycosylated bacterial metabolite | Glycan Bioscience LLC (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2421877-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | Glycan Biosciences Pty Ltd (AU) | 2012-02-29 | — | — | EP | disclosed |
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-04 | — | — | US | disclosed |
| WO-2010037179-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | CA2 1574/4885CA1 1192/4885CA12 243/4885 |
| US-20160303243-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | CA2 1574/4885CA1 1192/4885CA12 243/4885 |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | GNE, CD44, FUT5 | CA2 1574/4885CA1 1192/4885CA12 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.